FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely cardiology. Risk factors are assessed: Teicholz ejection fraction (EF) of the left ventricle (%), collagen concentration - 1 (COL 1) (pg/ml) in blood serum on the first day and on day 12, body mass index (BMI) determination, determination of concentration of matrix metalloproteinase -2 (MMR-2), as well as the age of the patient. If the conditions are met, each risk factor is estimated at 1 point: Teicholtz EF (%) <57.0 - coefficient 20; COL 1 (1 day), pg/ml ≥29930.0 - coefficient 32; BMI ≥29.4 - coefficient 6; MMR-2, ng/ml ≥235.6 - coefficient 5; COL 1 (12 days), pg/ml ≥30368.0 - coefficient 24; age <50.0 - 13, if the conditions are not met, each risk factor is estimated at 0 points, in the absence of data on the risk factor 0.5 points; the corresponding obtained point values are multiplied by coefficients, and then the obtained values are added by all factors; and when receiving 53 points or more, the risk of developing cardiofibrosis is assessed as high.
EFFECT: method makes it possible to choose the optimal treatment tactics for each patient, taking into account the individually calculated risk.
1 cl, 3 dwg, 15 tbl, 1 ex
